$VCEL
Vericel Corp Stock $vcel

$vcel Overview Financials Valuation SEC Filings Company Website

2016 Q2 Form 10-Q Financial Statement

#000162828016016063 Filed on May 10, 2016

Income Statement

Concept	2016 Q2	2016 Q1	2015 Q1
Revenue	$12.82M	$14.11M	$10.85M
YoY Change	-5.64%	30.04%
Cost Of Revenue	$7.300M	$6.560M	$5.568M
YoY Change	5.78%	17.82%
Gross Profit	$5.523M	$7.548M	$5.281M
YoY Change	-17.43%	42.93%
Gross Profit Margin	43.07%	53.5%	48.68%
Selling, General & Admin	$6.449M	$6.004M	$5.476M
YoY Change	15.47%	9.64%	298.54%
% of Gross Profit	116.77%	79.54%	103.69%
Research & Development	$4.058M	$3.536M	$4.377M
YoY Change	20.45%	-19.21%	33.81%
% of Gross Profit	73.47%	46.85%	82.88%
Depreciation & Amortization	$470.0K	$445.0K	$328.0K
YoY Change	135.0%	35.67%	238.14%
% of Gross Profit	8.51%	5.9%	6.21%
Operating Expenses	$10.51M	$9.540M	$9.853M
YoY Change	17.34%	-3.18%	112.12%
Operating Profit	-$4.984M	-$1.992M	-$4.572M
YoY Change	120.04%	-56.43%	-1.57%
Interest Expense	$3.000K	$3.000K	$2.000K
YoY Change	50.0%	50.0%	0.0%
% of Operating Profit
Other Income/Expense, Net	$1.940M	-$1.658M	-$290.0K
YoY Change	1616.81%	471.72%	-78.52%
Pretax Income	-$3.040M	-$3.650M	-$4.860M
YoY Change	41.4%	-24.9%	-19.0%
Income Tax
% Of Pretax Income
Net Earnings	-$3.044M	-$3.650M	-$4.862M
YoY Change	41.45%	-24.93%	-18.9%
Net Earnings / Revenue	-23.74%	-25.87%	-44.82%
Basic Earnings Per Share
Diluted Earnings Per Share	-$134.0K	-$161.5K	-$204.3K
COMMON SHARES
Basic Shares Outstanding	23.93M shares	23.85M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q2	2016 Q1	2015 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$9.800M	$13.50M	$25.90M
YoY Change	-51.49%	-47.88%	194.32%
Cash & Equivalents	$9.800M	$13.50M	$25.90M
Short-Term Investments
Other Short-Term Assets	$1.046M	$662.0K	$845.0K
YoY Change	-53.92%	-21.66%	111.25%
Inventory	$2.393M	$1.942M	$2.005M
Prepaid Expenses
Receivables	$9.031M	$9.669M	$9.166M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$22.31M	$25.82M	$37.92M
YoY Change	-33.51%	-31.92%	310.56%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.351M	$4.393M	$3.446M
YoY Change	-5.74%	27.48%	436.76%
Goodwill
YoY Change
Intangibles	$2.778M	$2.847M	$3.127M
YoY Change	-9.13%	-8.95%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$7.129M	$7.240M	$6.573M
YoY Change	-7.09%	10.15%	923.83%
TOTAL ASSETS
Total Short-Term Assets	$22.31M	$25.82M	$37.92M
Total Long-Term Assets	$7.129M	$7.240M	$6.573M
Total Assets	$29.43M	$33.06M	$44.49M
YoY Change	-28.59%	-25.7%	350.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.305M	$6.293M	$6.726M
YoY Change	-13.32%	-6.44%	169.04%
Accrued Expenses	$82.00K	$16.00K	$154.0K
YoY Change	-41.43%	-89.61%	-61.5%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$11.46M	$13.77M	$12.62M
YoY Change	5.89%	9.07%	106.65%
LONG-TERM LIABILITIES
Long-Term Debt	$52.00K	$62.00K	$100.0K
YoY Change	-42.86%	-38.0%
Other Long-Term Liabilities	$800.0K		$66.00K
YoY Change	1112.12%
Total Long-Term Liabilities	$52.00K	$62.00K	$166.0K
YoY Change	-66.88%	-62.65%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.46M	$13.77M	$12.62M
Total Long-Term Liabilities	$52.00K	$62.00K	$166.0K
Total Liabilities	$12.33M	$13.83M	$12.79M
YoY Change	12.32%	8.14%	109.67%
SHAREHOLDERS EQUITY
Retained Earnings	-$330.7M	-$327.7M
YoY Change
Common Stock	$309.4M	$308.5M	$305.9M
YoY Change	0.92%	0.84%	18.06%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$3.150M	$3.150M
YoY Change
Treasury Stock Shares
Shareholders Equity	$17.11M	$19.23M	$31.70M
YoY Change
Total Liabilities & Shareholders Equity	$29.43M	$33.06M	$44.49M
YoY Change	-28.59%	-25.7%	350.42%

Cashflow Statement

Concept	2016 Q2	2016 Q1	2015 Q1
OPERATING ACTIVITIES
Net Income	-$3.044M	-$3.650M	-$4.862M
YoY Change	41.45%	-24.93%	-18.9%
Depreciation, Depletion And Amortization	$470.0K	$445.0K	$328.0K
YoY Change	135.0%	35.67%	238.14%
Cash From Operating Activities	-$5.130M	-$1.270M	-$4.110M
YoY Change	14.51%	-69.1%	-11.99%
INVESTING ACTIVITIES
Capital Expenditures	-$1.060M	-$10.00K	-$350.0K
YoY Change	-12.4%	-97.14%
Acquisitions		$13.00K	$353.0K
YoY Change		-96.32%
Other Investing Activities	$0.00	-$93.00K	-$35.00K
YoY Change		165.71%
Cash From Investing Activities	-$1.060M	$80.00K	-$320.0K
YoY Change	-11.67%	-125.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.490M	150.0K	-10.00K
YoY Change		-1600.0%	-100.18%
NET CHANGE
Cash From Operating Activities	-5.130M	-1.270M	-4.110M
Cash From Investing Activities	-1.060M	80.00K	-320.0K
Cash From Financing Activities	2.490M	150.0K	-10.00K
Net Change In Cash	-3.700M	-1.040M	-4.440M
YoY Change	-34.86%	-76.58%	-669.23%
FREE CASH FLOW
Cash From Operating Activities	-$5.130M	-$1.270M	-$4.110M
Capital Expenditures	-$1.060M	-$10.00K	-$350.0K
Free Cash Flow	-$4.070M	-$1.260M	-$3.760M
YoY Change	24.46%	-66.49%	-19.49%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q1	astm	Common Stock Remaining Capacity CommonStockRemainingCapacity	7800000	USD
CY2011Q3	astm	Common Stock Value Registeredon Form S3 CommonStockValueRegisteredonFormS3	100000000	USD
CY2016Q1	astm	Convertible Preferred Stock Conversion Period ConvertiblePreferredStockConversionPeriod	P5Y
CY2015Q4	astm	Convertible Preferred Stock Maximum Beneficial Ownership Percentage ConvertiblePreferredStockMaximumBeneficialOwnershipPercentage	0.0999
CY2015Q4	astm	Convertible Preferred Stock Maximum Beneficial Ownership Percentage Upon Holders Election ConvertiblePreferredStockMaximumBeneficialOwnershipPercentageUponHoldersElection	0.1499
CY2016Q1	astm	Operatingand Capital Leasesand Purchase Commitments Future Minimum Payments Due OperatingandCapitalLeasesandPurchaseCommitmentsFutureMinimumPaymentsDue	27474000	USD
CY2016Q1	astm	Operatingand Capital Leasesand Purchase Commitments Future Minimum Payments Due Current OperatingandCapitalLeasesandPurchaseCommitmentsFutureMinimumPaymentsDueCurrent	3995000	USD
CY2016Q1	astm	Operatingand Capital Leasesand Purchase Commitments Future Minimum Payments Due In Four Years OperatingandCapitalLeasesandPurchaseCommitmentsFutureMinimumPaymentsDueInFourYears	4262000	USD
CY2016Q1	astm	Operatingand Capital Leasesand Purchase Commitments Future Minimum Payments Due In Three Years OperatingandCapitalLeasesandPurchaseCommitmentsFutureMinimumPaymentsDueInThreeYears	4614000	USD
CY2016Q1	astm	Operatingand Capital Leasesand Purchase Commitments Future Minimum Payments Due In Two Years OperatingandCapitalLeasesandPurchaseCommitmentsFutureMinimumPaymentsDueInTwoYears	4942000	USD
CY2016Q1	astm	Operatingand Capital Leasesand Purchase Commitments Future Minimum Payments Due Thereafter OperatingandCapitalLeasesandPurchaseCommitmentsFutureMinimumPaymentsDueThereafter	9661000	USD
CY2016Q1	dei	Amendment Flag AmendmentFlag	false
CY2016Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2016Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2016Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
CY2016Q1	dei	Document Period End Date DocumentPeriodEndDate	2016-03-31
CY2016Q1	dei	Document Type DocumentType	10-Q
CY2016Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000887359
CY2016Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	23934124	shares
CY2016Q1	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2016Q1	dei	Entity Registrant Name EntityRegistrantName	Vericel Corp
CY2015Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3603000	USD
CY2016Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	4943000	USD
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7588000	USD
CY2016Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	6293000	USD
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	10919000	USD
CY2016Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9669000	USD
CY2015Q4	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	1956000	USD
CY2016Q1	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	2584000	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	75000	USD
CY2016Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	16000	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5638000	USD
CY2016Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5918000	USD
CY2015Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	USD
CY2016Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	86000	USD
CY2016Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	USD
CY2015Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4200000	shares
CY2016Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6200000	shares
CY2015Q4	us-gaap	Assets Assets	34309000	USD
CY2016Q1	us-gaap	Assets Assets	33057000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	27343000	USD
CY2016Q1	us-gaap	Assets Current AssetsCurrent	25817000	USD
CY2015Q1	us-gaap	Business Combination Bargain Purchase Gain Recognized Amount BusinessCombinationBargainPurchaseGainRecognizedAmount	0	USD
CY2016Q1	us-gaap	Business Combination Bargain Purchase Gain Recognized Amount BusinessCombinationBargainPurchaseGainRecognizedAmount	-17000	USD
CY2016Q1	us-gaap	Capital Lease Obligations CapitalLeaseObligations	107000	USD
CY2016Q1	us-gaap	Capital Leases Future Minimum Payments Due Current CapitalLeasesFutureMinimumPaymentsDueCurrent	32000	USD
CY2016Q1	us-gaap	Capital Leases Future Minimum Payments Due In Five Years CapitalLeasesFutureMinimumPaymentsDueInFiveYears	0	USD
CY2016Q1	us-gaap	Capital Leases Future Minimum Payments Due In Four Years CapitalLeasesFutureMinimumPaymentsDueInFourYears	0	USD
CY2016Q1	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears	32000	USD
CY2016Q1	us-gaap	Capital Leases Future Minimum Payments Due In Two And Three Years CapitalLeasesFutureMinimumPaymentsDueInTwoAndThreeYears	43000	USD
CY2013Q4	us-gaap	Cash Cash	30343000	USD
CY2014Q1	us-gaap	Cash Cash	25903000	USD
CY2015Q4	us-gaap	Cash Cash	14581000	USD
CY2016Q1	us-gaap	Cash Cash	13544000	USD
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2016Q1	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2016Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23786000	shares
CY2016Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23891000	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23786000	shares
CY2016Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23786000	shares
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	307766000	USD
CY2016Q1	us-gaap	Common Stock Value CommonStockValue	308512000	USD
CY2015Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4933000	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3650000	USD
CY2015Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	5568000	USD
CY2016Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	6560000	USD
CY2015Q4	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	0	USD
CY2016Q1	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	-97000	USD
CY2015Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	328000	USD
CY2016Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	445000	USD
CY2015Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.27
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.24
CY2015Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1341000	USD
CY2016Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1959000	USD
CY2015Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	317000	USD
CY2016Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1640000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	1517000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	210000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	280000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	280000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	280000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	280000	USD
CY2016Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2847000	USD
CY2015Q1	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	16000	USD
CY2016Q1	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-10000	USD
CY2015Q1	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	35000	USD
CY2016Q1	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	USD
CY2015Q1	us-gaap	Gross Profit GrossProfit	5281000	USD
CY2016Q1	us-gaap	Gross Profit GrossProfit	7548000	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	460000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1976000	USD
CY2015Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-394000	USD
CY2016Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	1340000	USD
CY2015Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	85000	USD
CY2016Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	580000	USD
CY2015Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-191000	USD
CY2016Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	229000	USD
CY2015Q1	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-36000	USD
CY2016Q1	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	24000	USD
CY2015Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	975000	USD
CY2016Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-1250000	USD
CY2015Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2917000	USD
CY2016Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2847000	USD
CY2015Q1	us-gaap	Interest Expense InterestExpense	2000	USD
CY2016Q1	us-gaap	Interest Expense InterestExpense	3000	USD
CY2015Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	20000	USD
CY2016Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	19000	USD
CY2015Q4	us-gaap	Inventory Net InventoryNet	1379000	USD
CY2016Q1	us-gaap	Inventory Net InventoryNet	1942000	USD
CY2015Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1228000	USD
CY2016Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	1691000	USD
CY2015Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	131000	USD
CY2016Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	232000	USD
CY2015Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	13000	USD
CY2016Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	5000	USD
CY2015Q4	us-gaap	Liabilities Liabilities	12179000	USD
CY2016Q1	us-gaap	Liabilities Liabilities	13831000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	34309000	USD
CY2016Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	33057000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12108000	USD
CY2016Q1	us-gaap	Liabilities Current LiabilitiesCurrent	13769000	USD
CY2016Q1	us-gaap	Line Of Credit Facility Remaining Borrowing Capacity LineOfCreditFacilityRemainingBorrowingCapacity	7800000	USD
CY2015Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	71000	USD
CY2016Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	62000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-4440000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-1037000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-9000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	152000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-318000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	80000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4113000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-1269000	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-4862000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-3650000	USD
CY2015Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6452000	USD
CY2016Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5454000	USD
CY2015Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-290000	USD
CY2016Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1658000	USD
CY2016Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2015Q1	us-gaap	Operating Expenses OperatingExpenses	9853000	USD
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	9540000	USD
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4572000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1992000	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	26617000	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	4262000	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	4582000	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	4899000	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	9661000	USD
CY2016Q1	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	3213000	USD
CY2016Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1200000	USD
CY2015Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	231000	USD
CY2016Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	384000	USD
CY2015Q4	us-gaap	Other Assets Current OtherAssetsCurrent	464000	USD
CY2016Q1	us-gaap	Other Assets Current OtherAssetsCurrent	662000	USD
CY2015Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-71000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2015Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	160000	USD
CY2016Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	136000	USD
CY2015Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2016Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-10000	USD
CY2015Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-35000	USD
CY2016Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-93000	USD
CY2015Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	353000	USD
CY2016Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	13000	USD
CY2015Q1	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	458000	USD
CY2016Q1	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	706000	USD
CY2015Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1590000	USD
CY2016Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1804000	USD
CY2015Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	38389000	USD
CY2016Q1	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	38389000	USD
CY2015Q1	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	USD
CY2016Q1	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	258000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9687000	USD
CY2016Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	10311000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4049000	USD
CY2016Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4393000	USD
CY2016Q1	us-gaap	Purchase Obligation PurchaseObligation	750000	USD
CY2016Q1	us-gaap	Purchase Obligation Due In Fifth Year PurchaseObligationDueInFifthYear	0	USD
CY2016Q1	us-gaap	Purchase Obligation Due In Fourth Year PurchaseObligationDueInFourthYear	0	USD
CY2016Q1	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	750000	USD
CY2016Q1	us-gaap	Purchase Obligation Due In Second Year PurchaseObligationDueInSecondYear	0	USD
CY2016Q1	us-gaap	Purchase Obligation Due In Third Year PurchaseObligationDueInThirdYear	0	USD
CY2015Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	9000	USD
CY2016Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	9000	USD
CY2015Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4377000	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3536000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-324025000	USD
CY2016Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-327675000	USD
CY2015Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	10849000	USD
CY2016Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	14108000	USD
CY2015Q1	us-gaap	Sales Revenue Net SalesRevenueNet	10849000	USD
CY2016Q1	us-gaap	Sales Revenue Net SalesRevenueNet	14108000	USD
CY2015Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5476000	USD
CY2016Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6004000	USD
CY2015Q1	us-gaap	Share Based Compensation ShareBasedCompensation	922000	USD
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	488000	USD
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	76687000	USD
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	8116912000	USD
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	1430199000	USD
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	5000000	USD
CY2016Q1	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	42481	shares
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	22130000	USD
CY2016Q1	us-gaap	Stockholders Equity StockholdersEquity	19226000	USD
CY2015Q4	us-gaap	Treasury Stock Value TreasuryStockValue	3150000	USD
CY2016Q1	us-gaap	Treasury Stock Value TreasuryStockValue	3150000	USD
CY2015Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	757000	USD
CY2016Q1	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	2397000	USD
CY2015Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	23786000	shares
CY2016Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	22604000	shares
CY2016Q1	us-gaap	Basis Of Accounting BasisOfAccounting	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements included herein have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (SEC).  The preparation of condensed consolidated financial statements in conformity with generally accepted accounting principles in the United States of America (U.S. GAAP) requires management to make estimates, judgments, and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations. The financial statements reflect, in the opinion of management, all adjustments (consisting only of normal, recurring adjustments) necessary to state fairly the financial position and results of operations as of and for the periods indicated.  The results of operations for the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2016</font><font style="font-family:inherit;font-size:10pt;">, are not necessarily indicative of the results to be expected for the full year or for any other period.  The </font><font style="font-family:inherit;font-size:10pt;">March 31, 2016</font><font style="font-family:inherit;font-size:10pt;"> condensed consolidated balance sheet data was derived from the Company’s audited consolidated financial statements, but does not include all disclosures required by U.S. GAAP.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2015</font><font style="font-family:inherit;font-size:10pt;">, as filed with the SEC on March 14, 2016 (Annual Report).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consolidated financial statements include the accounts of Vericel and its wholly-owned subsidiaries, Marrow Donation, LLC, located in San Diego, California, and Vericel Denmark ApS, in Kastrup, Demark (collectively, the Company).  All inter-company transactions and accounts have been eliminated in consolidation.  Aastrom Biosciences GmbH ceased operations in 2014 and Marrow Donation, LLC and Vericel Denmark ApS ceased operations in 2015.</font></div></div>
CY2016Q1	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Organization</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vericel Corporation, a Michigan corporation, which was formerly known as Aastrom Biosciences, Inc. (the Company, Vericel, we, us or our), was incorporated in March 1989 and began employee-based operations in 1991. On May 30, 2014, Vericel completed the acquisition of certain assets and assumed certain liabilities of Sanofi, a French société anonyme (Sanofi), including all of the outstanding equity interests of Genzyme Biosurgery ApS (Genzyme Denmark or the Danish subsidiary) (now known as Vericel Denmark ApS), a wholly-owned subsidiary of Sanofi, and over </font><font style="font-family:inherit;font-size:10pt;">250</font><font style="font-family:inherit;font-size:10pt;"> patent applications of Sanofi and certain of its subsidiaries for purposes of acquiring the portion of the cell therapy and regenerative medicine business (the CTRM Business), which researches, develops, manufactures, markets and sells the Carticel</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;">, MACI™, and Epicel</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> products. The Company is a fully integrated, commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of innovative therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. Vericel has marketed products as well as developmental stage product candidates and the Company’s goal is to become the leader in cell therapy and regenerative medicine by developing, manufacturing and marketing best-in-class therapies for patients with significant unmet medical needs.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company operates its business primarily in the U.S. in </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> reportable segment — the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Successful future operations are subject to several technical hurdles and risk factors, including satisfactory product development, timely initiation and completion of clinical trials, regulatory approval and market acceptance of the Company’s products.</font></div></div>

Files In Submission

Name	View Source	Status
0001628280-16-016063-index-headers.html	Edgar Link	pending
0001628280-16-016063-index.html	Edgar Link	pending
0001628280-16-016063.txt	Edgar Link	pending
0001628280-16-016063-xbrl.zip	Edgar Link	pending
astm-20160331.xml	Edgar Link	completed
astm-20160331.xsd	Edgar Link	pending
astm-20160331_cal.xml	Edgar Link	unprocessable
astm-20160331_def.xml	Edgar Link	unprocessable
astm-20160331_lab.xml	Edgar Link	unprocessable
astm-20160331_pre.xml	Edgar Link	unprocessable
ex102dohmenservicesagreeme.htm	Edgar Link	pending
ex311q12016-ceocertificati.htm	Edgar Link	pending
ex312q12016cfocertification.htm	Edgar Link	pending
ex321q12016-ceosoxcertific.htm	Edgar Link	pending
ex322q12016-cfosoxcertific.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vericel3311610q.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VCEL
Vericel Corp Stock $vcel

2016 Q2 Form 10-Q Financial Statement

#000162828016016063 Filed on May 10, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VCEL Vericel Corp Stock $vcel

2016 Q2 Form 10-Q Financial Statement

#000162828016016063 Filed on May 10, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VCEL
Vericel Corp Stock $vcel